Pulmonary Rehabilitation Program

Pulmonary rehabilitation (PR) is defined by the American Thoracic Society (ATS) and European Respiratory Society (ERS) as 'a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors' (ATS/ERS Statement 2013, updated 2023).

Components: 1) Detailed patient assessment — medical history (diagnosis, severity, comorbidities, medications, prior exacerbations), physical examination, pulmonary function tests (spirometry, lung volumes, diffusion capacity), arterial blood gas, exercise capacity (6-minute walk test 6MWT distance — minimum clinically important difference 26-54 m, incremental shuttle walk test ISWT, cardiopulmonary exercise testing CPET maximum oxygen consumption VO2max), dyspnea scales (mMRC modified Medical Research Council 0-4, Borg 0-10), quality of life (St. George Respiratory Questionnaire SGRQ, COPD Assessment Test CAT, Chronic Respiratory Questionnaire CRQ), depression and anxiety screening (HADS Hospital Anxiety Depression Scale, PHQ-9), nutritional status (BMI, body composition with bioimpedance — fat-free mass index FFMI < 16 kg/m^2 in men, < 15 in women indicates muscle wasting), educational needs assessment; 2) Exercise training — supervised, individually prescribed, progressive endurance training (treadmill, bicycle ergometer, walking — target 60-80 percent of peak workload from CPET or 80-90 percent of average 6MWT speed, duration 20-60 minutes, frequency 3-5 sessions/week), resistance training (major muscle groups upper and lower extremity, 2-3 sets of 8-12 repetitions at 60-80 percent of one-repetition maximum 1RM, 2-3 sessions/week), flexibility training, breathing exercises (pursed-lip breathing, diaphragmatic breathing), inspiratory muscle training (threshold loading device 30-60 percent of maximum inspiratory pressure MIP); 3) Education — disease pathophysiology, medication use (inhaler technique imperative, demonstrate annually), self-management of exacerbations (action plan, when to seek help), smoking cessation (nicotine replacement, varenicline, bupropion, behavioral counseling), vaccination (annual influenza, pneumococcal PCV13/PCV15/PCV20 + PPSV23, COVID-19, RSV, pertussis), nutrition (adequate protein 1.2-1.5 g/kg/day, omega-3, vitamin D supplementation), oxygen therapy use, energy conservation techniques, panic and anxiety management; 4) Psychosocial support — group therapy, individual counseling, depression/anxiety treatment, coping strategies; 5) Long-term adherence — maintenance program, home exercise prescription, peer support, follow-up assessments.

Indications and evidence: 1) COPD — Class 1A evidence per GOLD 2024, indicated for symptomatic patients (mMRC ≥ 2 or CAT ≥ 10) with FEV1 < 80 percent or after exacerbation; outcomes — improved dyspnea (mMRC 0.5-1 point), exercise capacity (6MWT +50-90 m, ISWT +50 m), quality of life (SGRQ -8 points, CAT -3 points), decreased hospitalizations (NNT 4-6), decreased mortality (HR 0.42 vs usual care), cost-effectiveness $200-$1,000/QALY; 2) Interstitial lung disease — improvement in 6MWT, dyspnea, quality of life (Class 2B evidence); 3) Bronchiectasis, cystic fibrosis — exercise capacity, sputum clearance; 4) Asthma — uncontrolled severe asthma, useful adjunct; 5) Pre-lung transplant — preserve fitness, improve outcomes; 6) Post-lung transplant — recovery, return to function; 7) Lung cancer — pre-operative (NEAT trial), post-operative recovery, palliative; 8) Post-COVID-19 — emerging indication, growing evidence for long COVID with persistent dyspnea and fatigue; 9) Pulmonary hypertension — selected cases with cautious supervision; 10) Acute hospitalization — early mobilization in ICU and post-ICU rehabilitation.